Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
Summary
Serina Therapeutics drew the first $5 million tranche from a financing agreement that can provide up to $20 million. The company will use the proceeds to advance its registrational trial of SER-252 for advanced Parkinson’s disease. Serina has already submitted its IND to the FDA and secured initial ethics approval in Australia. The company expects to begin the global trial in Q4 2025 and dose the first patient before year-end.
Funding
Amount
$5.0M
Total raised
Date
October 6, 2025
Announcement date
Investors
-
Lead investors
Company
http://www.serinatherapeutics.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected